ABSTRACT: The development of nanoengineered particles, such as polymersomes, liposomes and polymer capsules, has the potential to offer significant advances in vaccine and cancer therapy.
cells exhibited capsules on the cell surface even when the target cells were present as less than 0.1% of the total cell population. Imaging flow cytometry was used to quantify the internalization of the capsules, and the target cells were found to internalize capsules efficiently. However, the role of the antibody in this process was determined to enhance accumulation of capsules on the cell surface rather than trigger receptor-mediated endocytosis. This represents a significant finding, as this is the first study into the role antibodies play in internalization of such capsules. It also opens up the possibility of targeting these capsules to cancer cells using targeting molecules that do not trigger an endocytic pathway. We envisage that this approach will be generally applicable to the specific targeting of a variety of nanoengineered materials to cells.
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The targeted delivery of drugs to specific cells has the potential to achieve therapeutically relevant doses at the site of action while minimizing potentially harmful side effects. [1] [2] [3] The development of therapeutic carriers that can deliver high payloads, while protecting the encapsulated drug from degradation, is currently of significant interest. Critical to targeted delivery is the ability to develop and functionalize drug delivery vehicles that exhibit low non-specific binding to cells using specific targeting molecules, such as antibodies, ligands and mimetics. 4, 5 This can be achieved via a number of methods, including carbodiimide, thiol/maleimide, and biotin/avidin coupling chemistries. 6 While these techniques have been applied previously for a number of applications, 6 there is an urgent need for coupling reactions that are stable in mild, aqueous conditions, that do not undergo unwanted side reactions and preserve the activity of the delicate targeting molecules.
An emerging coupling strategy is click chemistry, chiefly the Cu(I)-catalyzed azide-alkyne Huisgen cycloaddition reaction (CuAAC), which proceeds rapidly in mild aqueous conditions, undergoes negligible unwanted side reactions, and where the reactants are stable and largely unreactive until the addition of the Cu(I) catalyst. 7 Click chemistry has been used to couple a number of small targeting molecules, such as folate 8 and RGD peptides, to a variety of surfaces. 9, 10 However, until recently the use of CuAAC click chemistry to conjugate whole antibodies (Abs) to surfaces has been limited. [11] [12] [13] This is principally due to the presence of Cu(I), which triggers irreversible aggregation of the Ab. 11 Recently,
we developed a method to couple azide-functionalized Abs to alkyne-modified capsules using a chelated Cu(I) catalyst (Scheme 1, Figure S1 ), and demonstrated specific targeting to cancer cells, even when the target population is present as less than 0.1% of the total cell population. 11 Herein, we present a detailed investigation of the factors that influence the binding and internalization of such Abfunctionalized capsules to cancer cells. In this study we have explored the role of: (i) the capsule-to-cell ratio; (ii) the density of the Ab on the surface of the capsules; (iii) the percentage of target cells in a mixed cell population; and (iv) the type of Ab, on the binding and internalization of capsules by the cells.
The capsules used in this study were generated by layer-by-layer (LbL) deposition of alkyne-modified poly(N-vinylpyrrolidone) (PVPON Alk ) and poly(methacrylic acid) PMA on 585 nm-diameter silica spheres. 14 Assembly was performed at pH 4, where there is strong hydrogen bonding between the protonated carboxylic acid of PMA and the carbonyl oxygen of PVPON. Above the pK a of PMA (~pH 6.5), the hydrogen bonding is disrupted and the capsules disassemble. To impart stability at physiological conditions (pH 7.4), the alkyne groups on the PVPON Alk were cross-linked with a bifunctional poly(ethylene glycol) (PEG) azide. 14 This linker also contains a redox cleavable disulfide group that can degrade in the reducing conditions of the cellular cytoplasm. 15 After cross-linking and removal of the silica core with buffered hydrofluoric acid (HF), the capsules were placed in phosphate buffered saline (PBS) at pH 7, where the hydrogen bonding interaction between PMA and PVPON is disrupted, causing the PMA to be expelled from the film (during this process the capsules swell to be approximately 800 nm in diameter 14 ). This generates capsules formed exclusively from the low fouling polymer PVPON, held together with biologically cleavable disulfide bonds. Previously, we demonstrated that sufficient alkyne groups remain for subsequent functionalization of the film. 11, 14 While the work presented here focuses on the functionalization of capsules prepared using the LbL process, the general nature of click chemistry means that this approach is applicable to a variety of delivery techniques, including liposomes, micelles, polymersomes, and polyion complexes. 1, 16 The Ab chosen for this study was the humanized A33 monoclonal antibody (huA33 mAb), which has attracted considerable clinical attention for the targeting of colorectal cancer (CRC). 17 Greater than 95% of primary and metastatic colorectal cancers express the A33 antigen 17 and, in various clinical trials, A33 mAbs have been shown to localize specifically to human primary and metastatic CRC cells. Apart from its expression by normal intestinal and pyloric gastric epithelia, the A33 antigen exhibits very low or negligible expression by other tissues. 18 To attach the huA33mAb to the capsules using click chemistry, it first needs to be modified with azide groups. This may be achieved either in a site-specific manner, where the mAb is engineered to contain a C-terminal thioester that is reactive to a click modified peptide containing an N-terminal cysteine, 12 or by using amine-succinimidyl ester coupling chemistry. We previously demonstrated azide (Az) modification of the huA33 mAb by reacting it with a linear, bifunctional PEG that has a succinimidyl ester group at one end (reactive toward lysine) and an azide at the other (NHS-PEG2000-Az). The majority of the lysine residues (~65%) in huA33 mAb are located in the F c portion, so statistically the functionalization should occur preferentially in the Fc portion. 17 Using a 10-fold excess of NHS-PEG2000-Az, an average of one azide group was attached to the antibody, as determined by MALDI. 11 Broadening of the peak in the MALDI spectrum indicated that there was a range of functionalization, from 0-2 PEG Az per Ab.
The Ab functionalized capsules developed in this study, along with an understanding of how they interact with CRC cells, is likely to have significant implications for the development of carriers for cancer therapy, vaccines and gene therapy.
Results and Discussion
Capsule Functionalization. We have previously demonstrated the functionalization of capsules with Ab using AlexaFluor 647 (AF647) labeled huA33 mAb Az and IgG Az . 11 To gain a better understanding of the activity and specificity of the immobilized Abs, we probed the antigen binding using an AF488- Determining the exact amount of Ab immobilized onto the surface of the capsules is challenging, as cross-reactivity between the polymer and Cu(I) with standard in situ protein quantification reagents (e.g., microBCA or NanoOrange) interferes with the measurements. This small amount of residual Cu(I)
is unlikely to have a significant effect on cell viability, as recent studies have shown that chelated Cu(I) has minimal cellular toxicity. 19 We therefore immobilized AF488-huA33 mAb Az If the Ab density is too low, when a capsule comes in contact with the cell, there may be no Abs in the correct orientation to facilitate capsule binding.
Cell Targeting. The specific binding of huA33 mAb Az -functionalized capsules was investigated using AF647 labeled capsules incubated with the LIM1899 CRC cell line, 20 which expresses the A33 antigen on the cell surface. 21 Capsule binding was performed at 4 ºC for 1 h to eliminate variations that could be caused by internalization of the capsules. All experiments were performed in triplicate on the same day as variations in the cell density, deposition of extracellular matrix and passage number can affect the degree of capsule binding to cells. To determine the optimal concentration for targeting the cancer cells, the capsule-to-cell ratio was varied from 10:1 to 600:1 (Figure 2a ). Non-functionalized capsules and IgG Az -functionalized capsules showed a similar level of non-specific binding, which increased linearly to around 12% of cells at a 600:1 capsule-to-cell ratio. For huA33 mAb Az -functionalized capsules, the percentage of cells with capsules bound increased rapidly as the ratio was increased from 10:1 to 100:1.
At a 100:1 capsule-to-cell ratio, more than 85% of the cells had huA33 mAb Az -functionalized capsules bound. In contrast, only ~5% of the cells incubated with the IgG Az -and non-functionalized capsules had (Figure 3a ). This value was somewhat lower than that observed in Figure 2 , and is likely due to the variability observed in the culturing of the LIM1899 cells ( Figure S4 ). While the trends observed for these cells were consistent from day to day, the absolute values for the capsule binding varied by up to 20%. For this reason experiments were performed in triplicate on the same day.
There was no impact on the degree of non-specific binding as the amount of IgG Az was increased.
Interestingly, the fluorescence intensity of the cells, reflecting the number of capsules bound per cell, also increased as the density of the huA33 mAb Az on the capsule surface increased (Figures 3b and c) . cell ratio was kept constant at 100:1 in all experiments.
As we reported previously, greater than 90% of LIM2405+ cells bound huA33 mAb Az -functionalized capsules in a 50:50 mixture of LIM2405+:LIM2405-cells. 11 In contrast, less than 5% of LIM2405-cells bound capsules. 11 Similarly IgG Az -functionalized capsules showed low levels (<10%) of non-specific binding to both cell types. A higher degree of non-specific binding was observed for the LIM2405+ cells compared to the LIM2405-cells. This suggests the presence of the A33 molecule on the surface of the cell makes the cells more "adherent" and increases non-specific binding. In the current study, we demonstrate that when the proportion of LIM2405-cells is increased to a 4-fold excess over the LIM2405+ cells, the percentage of LIM2405+ cells with huA33 mAb Az -functionalized capsules bound remains at >80% ( Figure 5 ). Indeed, even when the LIM2405-:LIM2405+ cell ratio is increased to 10:1, 100:1 and 1000:1, more than 55% of the LIM2405+ cells bound huA33 mAb Az -functionalized capsules, while non-specific binding remains at less than 5%. This is potentially a significant result in a therapeutic context, as it demonstrates the ability to target a very small population of cells within a milieu of non-targeted cells. While a 100:1 ratio of capsules-to-target cells is required to give optimal targeting, the number of cells to be targeted can be very low. This result suggests that targeted antibody therapies are likely to have most impact in an adjuvant setting after the surgical removal of the primary tumour. Here the challenge is to kill undetectable deposits of metastatic cells (micrometastases) that have lodged in an organ distant from the primary tumor. While in vivo targeting of micrometastases is dependent on a number of additional factors, including blood circulation time of the capsules, and the vascularization, extravasation and penetration of the micrometastases, our data indicates that the capsule targeting system described here has potential use in such settings, 1 and warrants further investigation. with IgG-functionalized capsules contained internalized capsules (Figure 6a) . We counted the number of spots associated with each cell using the IDEAS software and assumed that each spot corresponds to 1 capsule. However, it is possible that some spots correspond to more than one capsule, resulting in an underestimation of the number of internalized capsules (Figure 7a-c) . The degree of internalization observed using the imaging flow cytometer was found to be consistent with higher resolution data obtained by using deconvolution microscopy ( Figure 7d ). (Figure 6b ). This can be attributed to the accumulation of a larger number of capsules on the cell surface, rather than the huA33 mAb triggering a specific receptor-mediated mechanism of internalization. In a previous study, we investigated the internalization of non-functionalized capsules prepared from PMA (rather than PVPON), and determined that unmodified capsules are most likely internalized via a non-specific "cell drinking" mechanism known as macropinocytosis. 22 The Ab-functionalized capsules were found to localize within the acidic lysosomes (data not shown), which is consistent with what we observed in our previous study for nonfunctionalized PMA capsules. 22 Similarly, De Geest and co-workers demonstrated that 3 µm-diameter dextran sulfate/poly-l-arginine capsules were internalized into dendritic cells via macropinocytosis. 23 This fits in well with the results reported here, whereby targeted capsules accumulate on the surfaces of cells via specific and high affinity antibody-antigen interactions and are then internalized via macropinocytosis. Once bound to the cell surface, either specifically in the case of huA33 mAb Azfunctionalized capsules or non-specifically for the IgG and non-functionalized capsules, the probability that the capsule will be internalized is the same, regardless of the binding mechanism. This suggests that the huA33 mAb strongly promotes the accumulation of targeted capsules on the surface of cells expressing the A33 antigen, which facilitates their internalization via an antibody-independent mechanism.
Internalization of Capsules into Cancer

Conclusion
Targeting aberrant cells and understanding how they interact with nanoengineered materials is critical for the development of better treatments for diseases such as cancer. In this study, we have interrogated the interaction of submicrometer-sized, low fouling, 14 huA33 mAb Az -functionalized PVPON capsules with human CRC cells. We found that the percentage of cells associated with capsules increases as the capsule-to-cell ratio increases to 100:1, reaching a plateau of 95% at a 600:1 ratio. However, the number of capsules associated with each cell continues to rise as the capsule-to-cell ratio increases. The density of the huA33 mAb on the surface of the capsules also influences both the percentage of cells with capsules bound and the total number of capsules associated with them. In mixed cell populations, the specific binding of the huA33 mAb Az -functionalized capsules is still effective, even when the target cells are present at less than 0.1% of the total cell population. When incubated with cells at 37 ºC for 2 h, significant internalization of the capsules is observed. This internalization is independent of capsule functionalization, suggesting a receptor-independent internalization mechanism, such as macropinocytosis. We anticipate that the results outlined here will have broad applicability for the targeting of a variety of nanoengineered particles, including polymersomes, liposomes, polyion complexes and inorganic nanoparticles.
Experimental
Methods. Capsule synthesis, 14 Ab modification 11 and fluorescence modification of capsules 14 were performed as described previously and are summarized in the Supporting Information. Figure S1 ). 24 Samples were incubated with constant shaking for 45 min at 4 °C and after functionalization the capsules were washed twice in PBS.
For flow cytometry and fluorescence microscopy measurements to qualitatively verify huA33 mAb conjugation ( Fig. 1) , capsules of ~3.8 μm-diameter were used.
Cell Targeting 
